Skip to content

Arcutis Biotherapeutics

US · ARQT #2465 by market cap Listed 2020
26.36 -0.81 -2.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.89 -1.03%
After-hours 26.40 +0.15%
34.0520.7926.362026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ARQT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +0.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 14.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 119.8x Better than 3%
Forward P/E 46.1x Better than 8%
Price / Sales 7.0x Better than 15%
P/E vs own 5-yr range 99th pctl Better than 5%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 90.2% Better than 97%
Operating margin -3.3% Better than 18%
Net margin -4.3% Better than 20%
Return on equity -9.3% Better than 21%
Return on invested capital -4.8% Better than 22%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 5.1% Better than 83%
6-month return 26.4% Better than 87%
12-month return (ex latest month) 5.8% Better than 41%
Distance below 52-week high 24.3% Better than 52%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.2x Better than 75%
Debt to assets 26.4% Better than 46%
Interest coverage -0.2x Better than 24%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 59.3% Better than 72%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.72%
1M -19.68%
3M +3.98%
6M +28.77%
YTD -9.23%
1Y -3.55%
3Y +1,173.43%
5Y +44.91%

Key statistics

Price & volume

Prev close
27.17
Open
26.91
Day range
26.29 - 27.47
Avg price
26.61
Volume
1.29M
Turnover
34.34M
Amplitude
4.36%
52-week range
19.30 - 34.80

Valuation

P/E
-202.77
P/E (TTM)
119.82
P/B
13.67
EPS
-0.13
Net profit
-16.44M
Net assets
243.93M

Share structure

Market cap
3.33B
Float cap
2.49B
Shares out
126.46M
Float shares
94.55M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-01-31
52-week range 46% of range
19.30 34.80

24.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.48M net over the window

Short interest

Shares short
18.16M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

Arcutis Biotherapeutics last traded at 26.36. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Arcutis Biotherapeutics's market cap?

About 3.33B.

What is the P/E ratio of Arcutis Biotherapeutics?

The trailing twelve-month P/E is 119.82. The Valuation tab shows it against the stock's own five-year range.

Does Arcutis Biotherapeutics pay a dividend?

Arcutis Biotherapeutics does not currently pay a regular dividend.

Is Arcutis Biotherapeutics a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 42.00, which implies 59.3% upside from the current price. This is not investment advice.

What is Arcutis Biotherapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Arcutis Biotherapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arcutis Biotherapeutics discussion 0 comments

Add a comment